Kymriah(tisagenlecleucel)
Kymriah (tisagenlecleucel) is a cell pharmaceutical. Tisagenlecleucel was first approved as Kymriah on 2017-08-30. It has been approved in Europe to treat large b-cell lymphoma diffuse and precursor b-cell lymphoblastic leukemia-lymphoma.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| hemic and lymphatic diseases | D006425 |
| immune system diseases | D007154 |
Trade Name
FDA
EMA
Kymriah
Drug Products
FDA
EMA
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| kymriah | Biologic Licensing Application | 2025-09-26 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
tisagenlecleucel, Kymriah, Novartis Pharmaceuticals Corporation | |||
| 2029-05-27 | Orphan excl. | ||
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| Q2042 | Tisagenlecleucel, up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose |
Clinical
Clinical Trials
90 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | — | C85.9 | 20 | 13 | 3 | — | 9 | 39 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 15 | 15 | 4 | — | 5 | 34 |
| Leukemia | D007938 | — | C95 | 19 | 14 | 2 | — | 1 | 29 |
| B-cell lymphoma | D016393 | — | — | 10 | 10 | 4 | — | 7 | 27 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 8 | 4 | 3 | — | 11 | 25 |
| Lymphoid leukemia | D007945 | — | C91 | 10 | 10 | 3 | — | 4 | 24 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 6 | 6 | 1 | — | 2 | 13 |
| Precursor t-cell lymphoblastic leukemia-lymphoma | D054218 | — | — | 3 | 7 | 1 | — | — | 11 |
| Follicular lymphoma | D008224 | — | C82 | 2 | 3 | 2 | — | 4 | 10 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 6 | 1 | 1 | — | 1 | 8 |
Show 2 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple myeloma | D009101 | — | C90.0 | 3 | 2 | — | — | 1 | 5 |
| Recurrence | D012008 | — | — | 1 | 2 | — | — | 1 | 4 |
| Hematologic neoplasms | D019337 | — | — | 2 | 1 | — | — | 2 | 4 |
| Biphenotypic leukemia acute | D015456 | — | C95.0 | 3 | 1 | — | — | 1 | 4 |
| Residual neoplasm | D018365 | — | — | 1 | 2 | — | — | — | 3 |
| Plasma cell neoplasms | D054219 | — | — | 2 | 1 | — | — | — | 3 |
| B-cell leukemia | D015448 | — | — | 2 | 2 | — | — | 1 | 3 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 1 | 1 | — | — | — | 1 |
| Myeloid leukemia | D007951 | — | C92 | 1 | 1 | — | — | — | 1 |
| Healthy volunteers/patients | — | — | — | 1 | 1 | — | — | — | 1 |
Show 4 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 2 | — | — | — | — | 2 |
| Cytokine release syndrome | D000080424 | — | D89.83 | 1 | — | — | — | 1 | 2 |
| Hodgkin disease | D006689 | — | C81 | 2 | — | — | — | — | 2 |
| Prolymphocytic leukemia | D015463 | — | — | 1 | — | — | — | 1 | 2 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myocarditis | D009205 | — | I51.4 | — | — | — | — | 1 | 1 |
| Adoptive immunotherapy | D016219 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Tisagenlecleucel |
| INN | tisagenlecleucel |
| Description | Tisagenlecleucel, sold under the brand name Kymriah, is a CAR T cells medication for the treatment of B-cell acute lymphoblastic leukemia (ALL) which uses the body's own T cells to fight cancer (adoptive cell transfer).
|
| Classification | Cell |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | 1986438 |
| ChEMBL ID | CHEMBL3301574 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB13881 |
| UNII ID | Q6C9WHR03O (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Kymriah – Novartis
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 7,274 documents
View more details
Safety
Black-box Warning
Black-box warning for: Kymriah
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
4,369 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use